What's at stake: Dual-listed respiratory company Fisher & Paykel Healthcare says a 15% US tariff on hospital products made in New Zealand won't impact its long-term plans.
Background: At its annual shareholder meeting, the company said the US tariff would have a 75 basis point impact on gross margin in FY26, or between $16m and $17m. That's factored into unchanged guidance for FY26 of operating revenue in the range of $2.15b to $2.25b and net profit after tax in the range of $390m to $440m.
Neville Mitchell, chair of dual-listed respiratory company Fisher & Paykel Healthcare, says it is not looking to make substantive changes despite the imposition of US tariffs.
The company told shareholders at yesterday’s annual meeting there would be an estimated 75 basis point impact on gross
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: Dual-listed respiratory company Fisher & Paykel Healthcare says a 15% US tariff on hospital products made in New Zealand won't impact its long-term plans.
Background: At its annual shareholder meeting, the company said the US tariff would have a 75 basis point impact on gross margin in FY26, or between $16m and $17m. That's factored into unchanged guidance for FY26 of operating revenue in the range of $2.15b to $2.25b and net profit after tax in the range of $390m to $440m.
